Join Us 
Bharat Biotech addressed concerns on Thursday regarding the safety of its Covid-19 vaccine, Covaxin, emphasizing its excellent safety record. The Hyderabad-based company stated that Covaxin had not been associated with any serious vaccine-related incidents, such as blood clots or thrombocytopenia. This reassurance comes amidst global scrutiny over the safety of Covid vaccines, particularly after AstraZeneca acknowledged rare side effects linked to its Covishield vaccine.
Covaxin, developed with a stringent focus on safety first and efficacy second, underwent extensive evaluation during its licensure process. Bharat Biotech highlighted that over 27,000 subjects participated in efficacy trials in India, making it the only Covid-19 vaccine in the country’s immunization program to undergo such rigorous testing. Additionally, ongoing safety monitoring, conducted by both the company and the Ministry of Health, ensured continuous evaluation of Covaxin’s safety profile.
The company’s commitment to patient safety was evident in its approach to vaccine development. Bharat Biotech stressed that while the efficacy of Covid-19 vaccines might wane over time, the impact on patient safety could last a lifetime. Therefore, ensuring the safety of Covaxin remained paramount throughout its development and deployment, reflecting the company’s dedication to public health.
[tta_listen_btn]
